Blood derived products in pediatrics: New laboratory tools for optimizing potency assignment and reducing side...

Area of Science:

• Pediatric Hematology
• Transfusion Medicine
• Biotechnology

Background:

• Neonates and children face rare bleeding disorders from coagulation factor deficiencies, allo-immune/autoimmune complications, or high-risk surgeries.
• Conventional blood-derived therapies, while improving prognosis, carry risks like immune tolerance and potential side effects.
• Recombinant proteins offer advantages in production scale and reduced viral transmission risks compared to plasma-extracted products.

Purpose of the Study:

• To review advancements in blood-derived and recombinant therapies for pediatric bleeding and thrombotic disorders.
• To highlight the role of improved manufacturing and analytical methods in minimizing adverse events.
• To discuss the evolving landscape of therapeutic products for rare bleeding conditions in children.

Main Methods:

• Review of current literature on blood-derived products, plasma-extracted products, and recombinant proteins.
• Analysis of advancements in manufacturing processes and quality control measures.
• Discussion of emerging analytical methods for product characterization and safety assessment.

Main Results:

• Recombinant proteins increasingly replace plasma-extracted products, offering safety and efficacy benefits.
• Progress in analytical methods allows better control of manufacturing processes, reducing side effects.
• New methods identify contaminants like activated coagulation Factors and extracellular vesicles (EVs), improving product safety.

Conclusions:

• Therapeutic products, including blood components, plasma derivatives, and recombinant proteins, significantly improve quality of life for pediatric patients.
• Enhanced manufacturing controls and analytical testing are crucial for minimizing adverse events such as thrombosis and anaphylaxis.
• Continued innovation in biotechnology and analytical techniques ensures the ongoing safety and efficacy of treatments for rare bleeding disorders.